Those results, together with the reported genetic differences between ADC and SCC histologies (Sos et al, 2009; Mountzios et al, 2010; Takahashi et al, 2010; Weiss et al, 2010; Hammerman et al, 2011, 2012; Imielinski et al, 2012; Sos & Thomas, 2012), led us to explore the efficacy of anti-VEGF/VEGFR therapy in clinically relevant mouse models that resemble the most represented NSCLC histologies. Here, VEGFA is linked to non-small cell lung carcinoma.